Gadoversetamide
- Generic Name
- Gadoversetamide
- Drug Type
- Small Molecule
- Chemical Formula
- C20H34GdN5O10
- CAS Number
- 131069-91-5
- Unique Ingredient Identifier
- RLM74T3Z9D
- Background
Gadoversetamide, marketed under the trade name OptiMARK, is a gadolinium compound used as a contrast agent in magnetic resonance imaging (MRI), particularly imaging of the brain, spine and liver.
- Indication
Gadoversetamide is an MRI contrast agent used for MRI diagnostic procedures to provide increased enhancement and visualization of lesions of the brain, spine and liver, including tumors.
- Associated Conditions
- Liver Lesions, Spinal Cord Lesions, Intracranial lesion
Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies
- Conditions
- Coronary Artery DiseaseCAD
- Interventions
- First Posted Date
- 2013-09-25
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- Daniel S. Berman
- Target Recruit Count
- 44
- Registration Number
- NCT01949844
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric Patients
- First Posted Date
- 2010-03-25
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Guerbet
- Target Recruit Count
- 100
- Registration Number
- NCT01092754
- Locations
- 🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Cardinal Glennon Childrens Hospital, Saint Louis, Missouri, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.